Clarient Granted Exclusive License to Commercialize Cancer Biomarker by Minerva Biotechnologies

Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that privately held, Waltham, MA-based Minerva Biotechnologies has granted it the exclusive right to develop and commercialize a test that identifies the MUC1* protein, a biomarker researchers believe may be implicated in the spread of many cancers, including breast cancer.

"We believe MUC1* has the potential to have an impact on cancer diagnostics," said Clarient Chief Executive Officer Ron Andrews. "It's early in the evaluation process, but it may have significance in diagnosing, selecting therapy, and monitoring therapeutic efficacy in solid tumors. Early research has also demonstrated that MUC1* may play a role in developing resistance to cancer drugs, which means if you can block MUC1*, you may be able to overcome resistance to a drug and, once again, offer that therapy."

Abingdon, United Kingdom, 2nd November 2009 – Toumaz Technology Limited, the leading provider of ultra-low power wireless infrastructure for body monitoring solutions and wholly owned subsidiary of Toumaz Holdings (AIM: TMZ.L), today announces that it has begun clinical trials of its Sensium™ “digital plaster” wireless body monitor. The trial of the ultra-low power, ultra-small size body monitoring system is being conducted by a specialist clinical research team at Imperial College London. The study, which is being funded by global healthcare corporation CareFusion (a recent spin-out of Cardinal Health) and conducted at St Mary’s Hospital (part of Imperial College Healthcare NHS Trust) is expected to demonstrate the high quality physiological data that can be continuously acquired by wireless, unobtrusive Sensium-enabled devices. Initial results are expected by the end of December this year.

In the milestone trial, volunteers and patient groups will be provided with a wearable Sensium digital “plaster” or “patch” that can continuously monitor multiple vital signs, including temperature, heart rate and respiration. The focus of the trial will be to verify that the physiological data acquired by the digital plaster system within a clinical setting is equivalent to that acquired using current gold-standard monitors in use in hospitals – equipment that is often bulky, expensive and fixed, such that patient mobility is impaired. The Sensium digital plaster is wireless and unobtrusive, meaning that patients can remain ambulatory in hospital while still being monitored. This flexibility allows continuous vital sign monitoring to be extended to patients who would not normally be monitored, thereby offering the potential to increase patient safety. The Sensium digital plaster is a disposable device with a working lifetime of several days, after which the plaster is disposed of in the appropriate waste receptacle.

The trial is being conducted in three phases, an initial phase with non-patient volunteers followed by two patient study groups: patients recovering from surgery, and patients with specific medical conditions in the general wards.

The digital plaster is based on Toumaz’s new generation AMx™ semiconductor IP platform, which enables Sensium wireless technology that has been specifically designed for Medical Body Area Networks (MBANs) and non-intrusive physiological monitoring. Sensium provides the complete wireless infrastructure to allow healthcare providers to monitor the human body continuously, wirelessly and intelligently and at low-cost, with the robustness and medical compliance normally associated with considerably more expensive capital equipment. Sensium technology has already been validated and CE marked in Toumaz’s Life Pebble non-disposable body worn monitoring devices.

The Sensium digital plaster is targeted for use in clinical monitoring applications such as acute care, general ward environments, tele-care, chronic disease monitoring, and in care home settings. For all these applications, disposability provides convenience, simplicity and patient comfort while ensuring infection control is maintained to the highest standards. Powered by thin batteries, body-worn Sensium-enabled monitors deliver clinical-quality data and intelligently integrate it into an electronic medical record via a network built on Toumaz’s power-optimised wireless operating and networking system, Nano Sensor Protocol (NSP).

Dr Stephen Brett, a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust and an Honorary Senior Lecturer at Imperial College London, who is leading the trial, explains: “This technology has the potential to improve the capturing of patient’s vital signs within all areas of the hospital – enabling key physiological data to be acquired at an increased frequency, with the minimum of inconvenience to patients, and without the requirement to connect patients to immobile pieces of equipment. This raises the possibility of technology: improving hospital safety systems; enhancing the efficiency of adding vital sign data to patient records: and potentially freeing valuable nursing staff time for other patient care responsibilities.”

“This is a very significant step on the path towards pervasive deployment of Sensium-enabled monitoring devices across a range of healthcare settings,” comments Toumaz Technology Co-Founder Keith Errey. “Current patient data acquisition systems are mostly hospital-based, expensive, generally wired, and non-mobile. Even so-called portable equipment is still large, and prohibitively expensive for widespread use. Our Sensium technology platform is the step change that enables the development of clinical grade yet low-cost and unobtrusive wireless body monitoring solutions for the first time. We are tremendously excited with the success so far of this important trial in partnership with Imperial College London.”

Professor Chris Toumazou FRS, CEO and Founder of Toumaz Holdings, and Director of the Institute of Biomedical Engineering at Imperial College London, adds: “It is fantastic to see the Sensium technology coming to commercial fruition, and for us to be launching this study at Imperial College Healthcare NHS Trust. This is a key stage in our commercial journey and one that opens the door to some very exciting applications of our technology in clinical environments next year.” He continues: “The business case is simple: by using the disposable digital plaster to monitor on a 24-7 basis, critical medical information can be monitored that would not otherwise have been detected. This preventative form of medicine will mean that less people could require intensive care in the future, saving lives and at the same time providing greater efficiencies and cost savings to the NHS. Once proven in a hospital setting then the digital plaster can be deployed in the home in the same way.”

Members of the media interested in scheduling a briefing with Toumaz can do so by contacting Nicky Denovan at toumaz[at]evokedset[dot]com.

– ends –

Notes to editors:

The new trial forms part of the Academic Health Science Centre (AHSC), a unique kind of partnership between Imperial College London and Imperial College Healthcare NHS Trust, formed in October 2007. The AHSC’s aim is to improve the quality of life of patients and populations by taking new discoveries and translating them into new therapies as quickly as possible.

About Sensium™

Toumaz Technology’s Sensium™ technology platform enables the non-intrusive acquisition of real-time, continuous physiological data for a wide range of health and lifestyle management applications, including remote healthcare, wellness and wireless monitoring at the bedside.

Sensium provides an open platform to develop revolutionary wireless devices that can continuously monitor multiple vital signs in real-time, and feed back high-quality information to health professionals via PCs, PDAs and smart phones.

About Toumaz Technology (www.toumaz.com)

Toumaz Technology Limited is the leading provider of ultra-low power wireless infrastructure for body monitoring solutions.

Toumaz’s ultra low-power smart sensor interface and transceiver platform – Sensium™ – enables non-intrusive, real-time wireless monitoring of multiple vital signs for a wide range of healthcare and lifestyle management applications. Based on Toumaz’s patented ultra-low power Advanced Mixed Signal (AMx)™ technology, the Sensium provides the enabling technology to connect the mobile individual to healthcare providers – simply, affordably and unobtrusively.

For healthcare professionals, this transforms the possibilities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible, personalised healthcare, as well as better therapeutic outcomes.

###

Press contacts:

Toumaz

Nicky Denovan

EvokedSet PR

toumaz [at] evokedset [dot] com

Phone: +44 (0)7747 017654

Distributed on behalf of Toumaz Technology by NeonDrum (http://www.neondrum.com) Nicky Denovan Tel: +44 7747 017654 nicky[at]neondrum[dot]com

Response Biomedical Obtains Special 510(k) U.S. FDA Clearance to Add Analytical Reactivity Information for the 2009 H1N1 Influenza A Virus to the RAMP(R) Influenza A/B Assay Package Insert

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that the Company has been granted a Special 510(k) U.S. FDA clearance for an update to the Company's RAMP(R) Influenza A/B Assay Package Insert to include analytical reactivity information for a strain of the 2009 H1N1 virus cultured from positive respiratory specimens. The RAMP(R) Influenza A/B Assay is marketed in the United States by 3M Health Care as the 3M(TM) Rapid Detection Flu A+B Test and is used to identify influenza A and B in human specimens.

DiagnoCure signs distribution agreement in the UK for its colorectal cancer test

DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland. Lab21 will offer the Previstage(TM) GCC test as part of its oncology testing services, and patient samples will be processed in DiagnoCure's U.S. clinical laboratory.

"This new partnership is a key initial step in reaching out to the European market. Lab21 is a leading provider of state-of-the-art diagnostics and world class customer service. This new avenue will support the global growth for our Previstage(TM) GCC Colorectal Cancer Staging Test," stated John C. Schafer, President and CEO of DiagnoCure.